ArticleFrontiers in endocrinology2026
From hypercalcemia to the diagnosis of pseudohypoparathyroidism type 1b: a case report.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudohypoparathyroidism type 1b (PHP-1b) is a rare genetic disorder caused by mutations or epigenetic alterations of the maternal GNAS gene, resulting in isolated renal resistance to parathyroid hormone (PTH) and, in some cases, partial resistance to thyroid-stimulating hormone. Clinical manifestations typically result from hypocalcemia and resemble those seen in hypoparathyroidism, while laboratory tests show elevated serum PTH levels along with hypocalcemia and hyperphosphatemia. We present a case of a girl with an unusual course of PHP: from non-autoimmune hypothyroidism coexisting with hypercalcemia at the age of 1 year to the diagnosis of PHP-1b at the age of 3.5 years, before the onset of symptomatic hypoparathyroidism. In the absence of a clear cause for hypothyroidism, assessment of calcium and phosphate metabolism should be considered. Initial hypercalcemia does not exclude the diagnosis of PHP-1b. Long-term monitoring of calcium and phosphate metabolism parameters may be necessary for a final clinical diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.